AIRLINK 191.84 Decreased By ▼ -1.66 (-0.86%)
BOP 9.87 Increased By ▲ 0.23 (2.39%)
CNERGY 7.67 Increased By ▲ 0.14 (1.86%)
FCCL 37.86 Increased By ▲ 0.16 (0.42%)
FFL 15.76 Increased By ▲ 0.16 (1.03%)
FLYNG 25.31 Decreased By ▼ -0.28 (-1.09%)
HUBC 130.17 Increased By ▲ 3.10 (2.44%)
HUMNL 13.59 Increased By ▲ 0.09 (0.67%)
KEL 4.67 Increased By ▲ 0.09 (1.97%)
KOSM 6.21 Increased By ▲ 0.11 (1.8%)
MLCF 44.29 Increased By ▲ 0.33 (0.75%)
OGDC 206.87 Increased By ▲ 3.63 (1.79%)
PACE 6.56 Increased By ▲ 0.16 (2.5%)
PAEL 40.55 Decreased By ▼ -0.43 (-1.05%)
PIAHCLA 17.59 Increased By ▲ 0.10 (0.57%)
PIBTL 8.07 Increased By ▲ 0.41 (5.35%)
POWER 9.24 Increased By ▲ 0.16 (1.76%)
PPL 178.56 Increased By ▲ 4.31 (2.47%)
PRL 39.08 Increased By ▲ 1.01 (2.65%)
PTC 24.14 Increased By ▲ 0.07 (0.29%)
SEARL 107.85 Increased By ▲ 0.61 (0.57%)
SILK 0.97 No Change ▼ 0.00 (0%)
SSGC 39.11 Increased By ▲ 2.71 (7.45%)
SYM 19.12 Increased By ▲ 0.08 (0.42%)
TELE 8.60 Increased By ▲ 0.36 (4.37%)
TPLP 12.37 Increased By ▲ 0.59 (5.01%)
TRG 66.01 Increased By ▲ 1.13 (1.74%)
WAVESAPP 12.78 Increased By ▲ 1.15 (9.89%)
WTL 1.70 Increased By ▲ 0.02 (1.19%)
YOUW 3.95 Increased By ▲ 0.10 (2.6%)
BR100 11,930 Increased By 162.4 (1.38%)
BR30 35,660 Increased By 695.9 (1.99%)
KSE100 113,206 Increased By 1719 (1.54%)
KSE30 35,565 Increased By 630.8 (1.81%)
World

Roche joins Moderna to include antibody test in COVID-19 vaccine trial

  • "This could play a role in assessing if, or when, an individual needs revaccination, or in helping to answer other clinically relevant questions," Roche said in a statement.
Published December 9, 2020

ZURICH: Roche is partnering with Moderna to include a COVID-19 antibody test in the mRNA specialist's ongoing vaccine trials, the Swiss drugmaker said on Wednesday, potentially demonstrating if the vaccine is working.

Roche said the test, which received US Food and Drug Administration emergency use approval in November, can provide quantitative evidence of the presence and levels of antibodies that develop in response to Moderna's vaccine candidate.

Moderna's vaccine, which in late-stage trials with more than 30,000 participants showed efficacy of 94% in preventing COVID-19, is designed to trigger an antibody response to proteins found on the coronavirus spike's receptor binding domain, the part of the virus that gains entry to human cells.

Roche said its test, conducted in a laboratory setting and requiring a blood draw, can establish a correlation between vaccine-induced protection and levels of receptor-binding domain antibodies.

"This could play a role in assessing if, or when, an individual needs revaccination, or in helping to answer other clinically relevant questions," Roche said in a statement.

Until now, demand for so-called molecular tests to detect active COVID-19 disease from Roche and other manufacturers has far exceeded supply, though there has been less demand for so-called antibody tests that help determine if a person has been exposed to the new coronavirus and has recovered.

Roche hopes with new tests like the one it is pairing with Moderna's trial will help boost demand for antibody tests, too.

Comments

Comments are closed.